Literature DB >> 33465527

SOD1 oligomers in amyotrophic lateral sclerosis.

Esther S Choi1, Nikolay V Dokholyan2.   

Abstract

Identifying nonnative, trimeric forms of SOD1 trimers as the toxic species, rather than large aggregates revolutionizes our understanding of ALS pathophysiology. Large protein aggregates, what was previously thought as the central cause of neurodegeneration, play protective role and are not responsible for neuronal death. SOD1 trimers are implicated at the molecular, cellular, and organismal level. Understanding the formation of the nonnative trimer and its role in the cell, leading to cell death, holds the key to developing a new standard of therapeutics for ALS and for other neurodegenerative diseases. This review highlights recent advances of knowledge for the role of SOD1 oligomers in ALS.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33465527      PMCID: PMC7965251          DOI: 10.1016/j.sbi.2020.12.002

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  51 in total

Review 1.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

2.  Stability and Local Unfolding of SOD1 in the Presence of Protein Crowders.

Authors:  Anna Bille; Kristine Steen Jensen; Sandipan Mohanty; Mikael Akke; Anders Irbäck
Journal:  J Phys Chem B       Date:  2019-02-26       Impact factor: 2.991

Review 3.  Amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

4.  Investigation of Anti-SOD1 Antibodies Yields New Structural Insight into SOD1 Misfolding and Surprising Behavior of the Antibodies Themselves.

Authors:  Ryan S Atlasi; Ravinder Malik; Christian I Corrales; Laura Tzeplaeff; Julian P Whitelegge; Neil R Cashman; Gal Bitan
Journal:  ACS Chem Biol       Date:  2018-08-30       Impact factor: 5.100

5.  A ditryptophan cross-link is responsible for the covalent dimerization of human superoxide dismutase 1 during its bicarbonate-dependent peroxidase activity.

Authors:  Danilo B Medinas; Fabio C Gozzo; Luiz F A Santos; Amadeu H Iglesias; Ohara Augusto
Journal:  Free Radic Biol Med       Date:  2010-06-30       Impact factor: 7.376

6.  Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models.

Authors:  Per Zetterström; Heather G Stewart; Daniel Bergemalm; P Andreas Jonsson; Karin S Graffmo; Peter M Andersen; Thomas Brännström; Mikael Oliveberg; Stefan L Marklund
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

7.  Improving symptom management for people with amyotrophic lateral sclerosis.

Authors:  Katharine Nicholson; Alyssa Murphy; Erin McDonnell; Jordan Shapiro; Ericka Simpson; Jonathan Glass; Hiroshi Mitsumoto; Dallas Forshew; Robert Miller; Nazem Atassi
Journal:  Muscle Nerve       Date:  2017-07-01       Impact factor: 3.217

8.  ALS-Linked Mutant SOD1 Associates with TIA-1 and Alters Stress Granule Dynamics.

Authors:  Do-Yeon Lee; Gye Sun Jeon; Jung-Joon Sung
Journal:  Neurochem Res       Date:  2020-10-06       Impact factor: 3.996

9.  Edaravone: A new drug approved for ALS.

Authors:  Jeffrey D Rothstein
Journal:  Cell       Date:  2017-11-02       Impact factor: 41.582

10.  An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS.

Authors:  Quan-Xiu Dong; Jie Zhu; Shu-Ying Liu; Xiao-Lin Yu; Rui-Tian Liu
Journal:  Int Immunopharmacol       Date:  2018-10-30       Impact factor: 4.932

View more
  5 in total

1.  Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS.

Authors:  Brianna Hnath; Nikolay V Dokholyan
Journal:  Biophys J       Date:  2022-05-03       Impact factor: 3.699

Review 2.  Neglected N-Truncated Amyloid-β Peptide and Its Mixed Cu-Zn Complexes.

Authors:  Tomasz Frączyk; Piotr Cieplak
Journal:  Protein J       Date:  2022-06-01       Impact factor: 4.000

Review 3.  Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.

Authors:  Belgin Sever; Halilibrahim Ciftci; Hasan DeMirci; Hilal Sever; Firdevs Ocak; Burak Yulug; Hiroshi Tateishi; Takahisa Tateishi; Masami Otsuka; Mikako Fujita; Ayşe Nazlı Başak
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

Review 4.  Biomarkers in Human Peripheral Blood Mononuclear Cells: The State of the Art in Amyotrophic Lateral Sclerosis.

Authors:  Orietta Pansarasa; Maria Garofalo; Eveljn Scarian; Francesca Dragoni; Jessica Garau; Rosalinda Di Gerlando; Luca Diamanti; Matteo Bordoni; Stella Gagliardi
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

Review 5.  Motor neuron-derived induced pluripotent stem cells as a drug screening platform for amyotrophic lateral sclerosis.

Authors:  Mariana A Amorós; Esther S Choi; Axel R Cofré; Nikolay V Dokholyan; Marcelo Duzzioni
Journal:  Front Cell Dev Biol       Date:  2022-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.